Baker Tilly Wealth Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Baker Tilly Wealth Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,668	Closed	-$249K	–	508
2023 Q2	$249K	Sell	10,668 -1,477	-12%	-$35.4K	0.03%	484
2023 Q1	$283K	Sell	12,145 -1,015	-8%	-$25.4K	0.03%	463
2022 Q4	$331K	Sell	13,160 -2,860	-18%	-$76.8K	0.04%	415
2022 Q3	$423K	Sell	16,020 -450	-3%	-$13.9K	0.06%	331
2022 Q2	$476K	Hold	16,470	–	–	0.06%	318
2022 Q1	$567K	Sell	16,470 -5,700	-26%	-$201K	0.06%	314
2021 Q4	$971K	Sell	22,170 -280	-1%	-$13.3K	0.1%	206
2021 Q3	$1.14M	Hold	22,450	–	–	0.15%	139
2021 Q2	$1.17M	Buy	22,450 +450	+2%	+$21.1K	0.19%	118
2021 Q1	$1.01M	Buy	22,000 +15,802	+255%	+$772K	0.21%	114
2020 Q4	$285K	Buy	+6,198	New	+$268K	0.09%	248

Other funds holding IDNA

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Baker Tilly Wealth Management's IDNA Position: Q3 2023 in Review

Baker Tilly Wealth Management sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2023, closing a stake of 10,668 shares — an estimated $249K sold.

Baker Tilly Wealth Management first reported a position in IDNA in Q4 2020 and held it in 11 quarters. The position peaked at $1.17M in Q2 2021. 66 funds tracked by Wall St. Rank hold IDNA as of Q3 2023.

Baker Tilly Wealth Management reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q3 2023 after selling out during the quarter.
Baker Tilly Wealth Management sold 10,668 iShares Genomics Immunology and Healthcare ETF shares in Q3 2023, an estimated $249K.
Baker Tilly Wealth Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2020 and held it in 11 quarters.
Baker Tilly Wealth Management's iShares Genomics Immunology and Healthcare ETF position peaked at $1.17M in Q2 2021.
66 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2023.

Based on Baker Tilly Wealth Management's 13F filing for Q3 2023, filed 10 Oct 2023.